These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer. Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763 [TBL] [Abstract][Full Text] [Related]
24. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis. Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439 [TBL] [Abstract][Full Text] [Related]
25. Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer. Workel HH; van Rooij N; Plat A; Spierings DCJ; Fehrmann RSN; Nijman HW; de Bruyn M Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471032 [TBL] [Abstract][Full Text] [Related]
26. BMDCs induce the generation of the CD103 Huang Y; Zhou L; Zhang H; Zhang L; Xi X; Sun Y Cell Immunol; 2022 Apr; 374():104502. PubMed ID: 35306373 [TBL] [Abstract][Full Text] [Related]
27. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation. Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C Front Immunol; 2020; 11():577. PubMed ID: 32391001 [TBL] [Abstract][Full Text] [Related]
28. Phenotypic Differences of CD103+ Tissue-Resident Memory T Cells Associated with Various Cancers. Park HS; Jeon Y; Lee H; Lee H; Kim YA; Park IA; Bang WS; Lee M; Cho YJ; Kim J; Gong G; Lee HJ Pathobiology; 2022; 89(2):116-126. PubMed ID: 34592745 [TBL] [Abstract][Full Text] [Related]
29. NUDT1 promotes the accumulation and longevity of CD103 Huang B; Lyu Z; Qian Q; Chen Y; Zhang J; Li B; Li Y; Liang J; Liu Q; Li Y; Chen R; Lian M; Xiao X; Miao Q; Wang Q; Fang J; Lian Z; Li Y; Tang R; Helleday T; Gershwin ME; You Z; Ma X J Hepatol; 2022 Nov; 77(5):1311-1324. PubMed ID: 35753523 [TBL] [Abstract][Full Text] [Related]
31. Significance of IL-17A-producing CD8 Kurihara K; Fujiyama T; Phadungsaksawasdi P; Ito T; Tokura Y J Dermatol Sci; 2019 Jul; 95(1):21-27. PubMed ID: 31300254 [TBL] [Abstract][Full Text] [Related]
32. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
33. Tissue-resident memory T cells in tumor immunity and immunotherapy. Okła K; Farber DL; Zou W J Exp Med; 2021 Apr; 218(4):. PubMed ID: 33755718 [TBL] [Abstract][Full Text] [Related]
34. Resident Memory T Cells in the Tumor Microenvironment. Williams JB; Kupper TS Adv Exp Med Biol; 2020; 1273():39-68. PubMed ID: 33119875 [TBL] [Abstract][Full Text] [Related]
35. Dopamine Signaling Promotes Tissue-Resident Memory Differentiation of CD8+ T Cells and Antitumor Immunity. Chen Y; Yan SM; Pu Z; Feng J; Tan L; Li Y; Hu H; Huang W; Lin Y; Peng Z; He X; Huang F; Zhang H; Zhang Y Cancer Res; 2022 Sep; 82(17):3130-3142. PubMed ID: 35802647 [TBL] [Abstract][Full Text] [Related]
36. Characterization of CD103 Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170 [TBL] [Abstract][Full Text] [Related]
37. CD103 fate mapping reveals that intestinal CD103 Fung HY; Teryek M; Lemenze AD; Bergsbaken T Sci Immunol; 2022 Nov; 7(77):eabl9925. PubMed ID: 36332012 [TBL] [Abstract][Full Text] [Related]
38. Intratumoral CD8 Virassamy B; Caramia F; Savas P; Sant S; Wang J; Christo SN; Byrne A; Clarke K; Brown E; Teo ZL; von Scheidt B; Freestone D; Gandolfo LC; Weber K; Teply-Szymanski J; Li R; Luen SJ; Denkert C; Loibl S; Lucas O; Swanton C; Speed TP; Darcy PK; Neeson PJ; Mackay LK; Loi S Cancer Cell; 2023 Mar; 41(3):585-601.e8. PubMed ID: 36827978 [TBL] [Abstract][Full Text] [Related]
39. Paxillin Binding to the Cytoplasmic Domain of CD103 Promotes Cell Adhesion and Effector Functions for CD8 Gauthier L; Corgnac S; Boutet M; Gros G; Validire P; Bismuth G; Mami-Chouaib F Cancer Res; 2017 Dec; 77(24):7072-7082. PubMed ID: 29021139 [TBL] [Abstract][Full Text] [Related]
40. Intratumoral TIGIT Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]